- call +1-201-465-4211
- email sales@mrinsights.biz
Asthma and chronic obstructive pulmonary disease (Asthma/COPD) are a common type of chronic disease. Once they are sick, they usually need long-term medication, which seriously affects people's quality of life.
Scope of the Report:
This report focuses on the Asthma and COPD Drug in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The 2016 Global Asthma Prevention Initiative (GINA) organization has re-released its Consensus on Asthma, COPD and Asthma-COPD Overlap Syndrome, developed in collaboration with the Global Scientific Committee on Chronic Obstructive Pulmonary Disease Prevention (GOLD). A method of identifying such patients is provided.
The worldwide market for Asthma and COPD Drug is expected to grow at a CAGR of roughly 6.2% over the next five years, will reach 7460 million US$ in 2023, from 5200 million US$ in 2017, according to a new study.
Market Segment by Manufacturers, this report covers
Boehringer Ingelheim
GlaxoSmithKline
Merck and Co
Novartis AG
AstraZeneca
F. Hoffmann-La Roche
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Bronchodilators
Anti-inflammatory Drugs
Monoclonal Antibodies
Combination Drugs
Market Segment by Applications, can be divided into
Asthma
COPD
There are 15 Chapters to deeply display the global Asthma and COPD Drug market.
Chapter 1, to describe Asthma and COPD Drug Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Asthma and COPD Drug, with sales, revenue, and price of Asthma and COPD Drug, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Asthma and COPD Drug, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Asthma and COPD Drug market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Asthma and COPD Drug sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 Asthma and COPD Drug Introduction
1.2 Market Analysis by Type
1.2.1 Bronchodilators
1.2.2 Anti-inflammatory Drugs
1.2.3 Monoclonal Antibodies
1.2.4 Combination Drugs
1.3 Market Analysis by Applications
1.3.1 Asthma
1.3.2 COPD
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Boehringer Ingelheim
2.1.1 Business Overview
2.1.2 Asthma and COPD Drug Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Boehringer Ingelheim Asthma and COPD Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 GlaxoSmithKline
2.2.1 Business Overview
2.2.2 Asthma and COPD Drug Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 GlaxoSmithKline Asthma and COPD Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Merck and Co
2.3.1 Business Overview
2.3.2 Asthma and COPD Drug Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Merck and Co Asthma and COPD Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Novartis AG
2.4.1 Business Overview
2.4.2 Asthma and COPD Drug Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Novartis AG Asthma and COPD Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 AstraZeneca
2.5.1 Business Overview
2.5.2 Asthma and COPD Drug Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 AstraZeneca Asthma and COPD Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 F. Hoffmann-La Roche
2.6.1 Business Overview
2.6.2 Asthma and COPD Drug Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 F. Hoffmann-La Roche Asthma and COPD Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Asthma and COPD Drug Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
3.1 Global Asthma and COPD Drug Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Asthma and COPD Drug Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 Asthma and COPD Drug Manufacturer Market Share in 2017
3.3.2 Top 6 Asthma and COPD Drug Manufacturer Market Share in 2017
3.4 Market Competition Trend
4 Global Asthma and COPD Drug Market Analysis by Regions
4.1 Global Asthma and COPD Drug Sales, Revenue and Market Share by Regions
4.1.1 Global Asthma and COPD Drug Sales and Market Share by Regions (2013-2018)
4.1.2 Global Asthma and COPD Drug Revenue and Market Share by Regions (2013-2018)
4.2 North America Asthma and COPD Drug Sales and Growth Rate (2013-2018)
4.3 Europe Asthma and COPD Drug Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific Asthma and COPD Drug Sales and Growth Rate (2013-2018)
4.5 South America Asthma and COPD Drug Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa Asthma and COPD Drug Sales and Growth Rate (2013-2018)
5 North America Asthma and COPD Drug by Countries
5.1 North America Asthma and COPD Drug Sales, Revenue and Market Share by Countries
5.1.1 North America Asthma and COPD Drug Sales and Market Share by Countries (2013-2018)
5.1.2 North America Asthma and COPD Drug Revenue and Market Share by Countries (2013-2018)
5.2 United States Asthma and COPD Drug Sales and Growth Rate (2013-2018)
5.3 Canada Asthma and COPD Drug Sales and Growth Rate (2013-2018)
5.4 Mexico Asthma and COPD Drug Sales and Growth Rate (2013-2018)
6 Europe Asthma and COPD Drug by Countries
6.1 Europe Asthma and COPD Drug Sales, Revenue and Market Share by Countries
6.1.1 Europe Asthma and COPD Drug Sales and Market Share by Countries (2013-2018)
6.1.2 Europe Asthma and COPD Drug Revenue and Market Share by Countries (2013-2018)
6.2 Germany Asthma and COPD Drug Sales and Growth Rate (2013-2018)
6.3 UK Asthma and COPD Drug Sales and Growth Rate (2013-2018)
6.4 France Asthma and COPD Drug Sales and Growth Rate (2013-2018)
6.5 Russia Asthma and COPD Drug Sales and Growth Rate (2013-2018)
6.6 Italy Asthma and COPD Drug Sales and Growth Rate (2013-2018)
7 Asia-Pacific Asthma and COPD Drug by Countries
7.1 Asia-Pacific Asthma and COPD Drug Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Asthma and COPD Drug Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific Asthma and COPD Drug Revenue and Market Share by Countries (2013-2018)
7.2 China Asthma and COPD Drug Sales and Growth Rate (2013-2018)
7.3 Japan Asthma and COPD Drug Sales and Growth Rate (2013-2018)
7.4 Korea Asthma and COPD Drug Sales and Growth Rate (2013-2018)
7.5 India Asthma and COPD Drug Sales and Growth Rate (2013-2018)
7.6 Southeast Asia Asthma and COPD Drug Sales and Growth Rate (2013-2018)
8 South America Asthma and COPD Drug by Countries
8.1 South America Asthma and COPD Drug Sales, Revenue and Market Share by Countries
8.1.1 South America Asthma and COPD Drug Sales and Market Share by Countries (2013-2018)
8.1.2 South America Asthma and COPD Drug Revenue and Market Share by Countries (2013-2018)
8.2 Brazil Asthma and COPD Drug Sales and Growth Rate (2013-2018)
8.3 Argentina Asthma and COPD Drug Sales and Growth Rate (2013-2018)
8.4 Colombia Asthma and COPD Drug Sales and Growth Rate (2013-2018)
9 Middle East and Africa Asthma and COPD Drug by Countries
9.1 Middle East and Africa Asthma and COPD Drug Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Asthma and COPD Drug Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa Asthma and COPD Drug Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia Asthma and COPD Drug Sales and Growth Rate (2013-2018)
9.3 UAE Asthma and COPD Drug Sales and Growth Rate (2013-2018)
9.4 Egypt Asthma and COPD Drug Sales and Growth Rate (2013-2018)
9.5 Nigeria Asthma and COPD Drug Sales and Growth Rate (2013-2018)
9.6 South Africa Asthma and COPD Drug Sales and Growth Rate (2013-2018)
10 Global Asthma and COPD Drug Market Segment by Type
10.1 Global Asthma and COPD Drug Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Asthma and COPD Drug Sales and Market Share by Type (2013-2018)
10.1.2 Global Asthma and COPD Drug Revenue and Market Share by Type (2013-2018)
10.2 Bronchodilators Sales Growth and Price
10.2.1 Global Bronchodilators Sales Growth (2013-2018)
10.2.2 Global Bronchodilators Price (2013-2018)
10.3 Anti-inflammatory Drugs Sales Growth and Price
10.3.1 Global Anti-inflammatory Drugs Sales Growth (2013-2018)
10.3.2 Global Anti-inflammatory Drugs Price (2013-2018)
10.4 Monoclonal Antibodies Sales Growth and Price
10.4.1 Global Monoclonal Antibodies Sales Growth (2013-2018)
10.4.2 Global Monoclonal Antibodies Price (2013-2018)
10.5 Combination Drugs Sales Growth and Price
10.5.1 Global Combination Drugs Sales Growth (2013-2018)
10.5.2 Global Combination Drugs Price (2013-2018)
11 Global Asthma and COPD Drug Market Segment by Application
11.1 Global Asthma and COPD Drug Sales Market Share by Application (2013-2018)
11.2 Asthma Sales Growth (2013-2018)
11.3 COPD Sales Growth (2013-2018)
12 Asthma and COPD Drug Market Forecast (2018-2023)
12.1 Global Asthma and COPD Drug Sales, Revenue and Growth Rate (2018-2023)
12.2 Asthma and COPD Drug Market Forecast by Regions (2018-2023)
12.2.1 North America Asthma and COPD Drug Market Forecast (2018-2023)
12.2.2 Europe Asthma and COPD Drug Market Forecast (2018-2023)
12.2.3 Asia-Pacific Asthma and COPD Drug Market Forecast (2018-2023)
12.2.4 South America Asthma and COPD Drug Market Forecast (2018-2023)
12.2.5 Middle East and Africa Asthma and COPD Drug Market Forecast (2018-2023)
12.3 Asthma and COPD Drug Market Forecast by Type (2018-2023)
12.3.1 Global Asthma and COPD Drug Sales Forecast by Type (2018-2023)
12.3.2 Global Asthma and COPD Drug Market Share Forecast by Type (2018-2023)
12.4 Asthma and COPD Drug Market Forecast by Application (2018-2023)
12.4.1 Global Asthma and COPD Drug Sales Forecast by Application (2018-2023)
12.4.2 Global Asthma and COPD Drug Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Asthma and COPD Drug Picture
Table Product Specifications of Asthma and COPD Drug
Figure Global Sales Market Share of Asthma and COPD Drug by Types in 2017
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
